Eleven Biotherapeutics Inc (NASDAQ:EBIO) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,799,497 shares, an increase of 70.2% from the January 12th total of 1,644,474 shares. Approximately 12.4% of the shares of the stock are short sold. Based on an average daily volume of 1,355,215 shares, the short-interest ratio is presently 2.1 days.
Separately, ValuEngine upgraded shares of Eleven Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
Eleven Biotherapeutics (NASDAQ:EBIO) traded down $0.03 during trading hours on Friday, hitting $0.81. 764,681 shares of the stock were exchanged, compared to its average volume of 1,027,110. Eleven Biotherapeutics has a 52 week low of $0.62 and a 52 week high of $2.54. The company has a market capitalization of $27.55, a PE ratio of -0.77 and a beta of 3.19.
Several large investors have recently bought and sold shares of EBIO. Virtu KCG Holdings LLC bought a new position in shares of Eleven Biotherapeutics in the second quarter valued at approximately $175,000. Vanguard Group Inc. raised its stake in shares of Eleven Biotherapeutics by 17.4% in the second quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 30,600 shares during the last quarter. Virtu Financial LLC raised its stake in shares of Eleven Biotherapeutics by 1,007.9% in the fourth quarter. Virtu Financial LLC now owns 427,048 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 388,502 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan bought a new position in shares of Eleven Biotherapeutics in the third quarter valued at approximately $382,000. Institutional investors own 3.84% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Eleven Biotherapeutics Inc (EBIO) Short Interest Update” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/09/eleven-biotherapeutics-inc-ebio-short-interest-update.html.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.